Fundraising FoxMassachusetts Avenue Capital
Venture capitalPre-Seed · 4 people tracked
Find your way into Massachusetts Avenue Capital
Sign up to see every warm intro you have to Massachusetts Avenue Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Massachusetts Avenue Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fund manager profile
Massachusetts Avenue Capital is a venture fund manager. SEC filings show 1 venture fund on record, most recently Massachusetts Avenue Capital Partners, L.P. ($3M offering) filed March 2016.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 4 people
from public directoriesFrequently asked questions
- What stage does Massachusetts Avenue Capital invest at?
- Massachusetts Avenue Capital invests at the Pre-Seed stage.
- What sectors does Massachusetts Avenue Capital focus on?
- Massachusetts Avenue Capital focuses on Crypto & Web3.
Similar investors
AirTree Ventures runs Pathfinders, a free four-week in-person program in Sydney for young builders (high-school graduates up to age 23) to work on a real product, access the AirTree team and founders, and build a peer network.
August Capital is a venture capital firm that invests in a small number of companies, providing hands-on support to entrepreneurs building their businesses.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blueyard is a small equal partnership with offices in the US and Europe, investing in early-stage companies.
Breyer Capital is an early-stage, high-conviction investment firm with a dedicated healthcare and life sciences practice backing founders rebuilding medicine at the intersection of science, data, care delivery, and economics.